Vaccines targeting shared / public neoantigens (e.g. recurrent KRAS and TP53 mutations) — an off-the-shelf alternative to fully personalized manufacture.
Ann & Robert H Lurie Children's Hospital of Chicago is recruiting for a Phase I trial of rHSC-DIPGVax, an off-the-shelf neoantigen heat shock protein vaccine containing 16 peptides, combined with BALSTILIMAB and ZALIFRELIMAB. The trial targets newly diagnosed DIPG and DMG patients who have completed radiation, aiming to assess safety and tolerability of this non-personalized approach.
A Science publication reports that healthy donor T cell receptors can expand functional neoantigen recognition beyond patient vaccination. This finding suggests potential for off-the-shelf TCR therapies or broader immune monitoring strategies that do not rely solely on patient-specific vaccine responses.
The Affiliated Nanjing Drum Tower Hospital is recruiting for a Phase 1/2 trial of a KRAS neoantigen nanovaccine derived from engineered Lactococcus lactis bacterial membranes. The vaccine is administered as adjuvant therapy to post-operative colorectal and pancreatic cancer patients with KRAS mutations, aiming to assess safety, immunogenicity, and preliminary efficacy in preventing recurrence.